Rationale and necessity for delivery of RRx-001, a Myc and CD47 antagonist, by intravenous blood mix

Expert Opin Drug Deliv. 2020 Jun;17(6):741-742. doi: 10.1080/17425247.2020.1761787. Epub 2020 Apr 30.

Authors

Scott Caroen¹, Bryan Oronsky¹, Corey Carter¹, Michelle Lybeck¹, Arnold Oronsky², Tony Reid¹

Affiliations

¹ Clinical Department, EpicentRx, Inc , La Jolla, CA, USA.
² Clinical Department, InterWest Partners , Menlo Park, CA, USA.

PMID: 32331501
DOI: 10.1080/17425247.2020.1761787

No abstract available

Keywords: CD47; MYC; Oncology; PD-L1; RRx-001; blood mix; intravenous infusion; small molecule.

Publication types

Editorial